Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Monitoring and Treating Frontal Fibrosing Alopecia: Practical Tips and Emerging Therapies
Description
The speaker reviews practical monitoring and treatment tips for frontal fibrosing alopecia (FFA), emphasizing that follow-up should include frontal hairline measurements, eyebrow loss, facial papules, and especially trichoscopy to assess vellus hair loss and inflammation. Because inflammation can be misleading on visual exam, standardized clinical, close-up, and trichoscopic photos at every visit are strongly recommended to better track progression. Treatment is presented as multi-pronged: topical options include corticosteroids, calcineurin inhibitors such as tacrolimus, and emerging topical JAK inhibitors like ruxolitinib, tofacitinib, and delgocitinib, though long-term efficacy data remain limited. Intralesional steroids can be used cautiously, ideally with low concentrations, small volumes, and sometimes combined with PRP to reduce atrophy risk. Systemic therapies discussed include classic agents and newer possibilities such as oral JAK inhibitors and brepocitinib, with the speaker noting promise but limited data. Oral 5-alpha-reductase inhibitors, especially dutasteride, are highlighted as helpful for disease control, and oral minoxidil is strongly recommended for both hairline/eyebrow improvement and possible slowing of progression. Symptom-focused care includes low-dose naltrexone, gabapentin, botulinum toxin for trichodynia, and lifestyle measures. Facial papules may respond to oral isotretinoin, and selected patients may benefit from micropigmentation or hair transplantation.
View moreConclusions
- Regular follow-up in frontal fibrosing alopecia should combine standardized clinical photos, close-up images, and trichoscopy rather than relying on visual inspection alone.
- Disease assessment should track both progression of the hairline recession and the degree of perifollicular inflammation, including vellus hair loss, eyebrow loss, and facial papules.
- Trichoscopy is essential because scalp redness may reflect steroid-induced dermatitis or seborrheic dermatitis rather than active FFA inflammation.
- Topical calcineurin inhibitors and topical JAK inhibitors may both have a role, with JAK inhibitors helping reduce inflammation and calcineurin inhibitors potentially helping preserve follicular immune privilege.
- Intralesional corticosteroids can be useful, but they should be given carefully with low volumes, low concentrations, shallow injections, and consideration of PRP to reduce atrophy risk.
- Systemic emerging therapies such as brepocitinib appear promising for cicatricial alopecias, but current evidence is still limited and longer follow-up is needed.
- Controlling inflammation alone is sometimes insufficient, because some patients continue to lose hair despite low visible inflammation, so treatment often needs to address progression directly.
- Oral 5-alpha-reductase inhibitors, especially dutasteride, appear to be among the most effective treatments for stabilizing FFA progression.
- Oral minoxidil may improve hair density and may also contribute to disease stabilization, not just cosmetic benefit.
- Facial papules can be treated with oral isotretinoin, but their appearance can vary during the day, so timing of assessment matters.
- Hair restoration options such as micropigmentation and transplantation can be considered in selected patients, but they require careful patient selection and realistic expectations.
- Overall, optimal FFA management is multimodal, targeting inflammation, progression, symptoms, and aesthetics at the same time.
- Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG). Medical Dermatology / British Journal of Dermatology.#10.1111/bjd.20567
- Olsen et al. Br J Dermatol. 2021.
- Steroid-induced changes in trichoscopy of patients with frontal fibrosing alopecia. JAAD. 2018.#10.5005/jp/books/14121_19
- Aubrey M. and Senna MM. J Invest Dermatol. 2025.
- Sanna MM, et al. JID Innov. 2022.
- A phase 2A trial of brepocitinib for cicatricial alopecia. JAAD. 2024.#10.1016/j.jaad.2024.09.073
- Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice. Journal of the American Academy of Dermatology.#10.1016/j.jaad.2021.02.089
- Matsui MS et al. International Journal of Molecular Sciences. 2016.
- Balaguera-Orjuela V, Saceda-Corralo D. Accepted in Actas Dermo-Sifiliograficas. 2025.